logo-loader

ProNAi shares lose two-thirds after abandoning trials and Wedbush downgrade

Last updated: 16:17 06 Jun 2016 EDT, First published: 11:17 06 Jun 2016 EDT

MedicalLab
ProNAi: Clinical trial abandoned and broker downgrade

ProNAi Therapeutics (NASDAQ:DNAI) shares closed down 67.6% at $2.07 after being downgraded by Wedbush brokers to Neutral from Outperform and price target to $3 from $36 after company said it was discontinuing its PNT2258 programme due to a lack of efficacy.

Wedbush also said: "we are stepping to the sidelines as the company refocuses to development of PNT141 and looks to acquire additional promising new assets."

Wedbush added: "Interim data from the Wolverine r/r DLBCL study shows only modest efficacy for PNT2258 in evaluable patients, with an 8.1% ORR, and 15% ORR in a response-evaluable subgroup (performance status of 0-1, exposure to 1-3 prior regimens, eight doses of PNT2258 within 35 days of starting therapy). No responses were observed in patients with a performance status (PS) of 2 and/or 4 or more lines of therapy."
 

Rush Rare Metals Advances Two Key Projects: Uranium in Wyoming and Niobium...

Rush Rare Metals CEO Peter Smith joined Steve Darling from Proactive to share news about the mineral exploration company's focus on its Boxi Property in Quebec and the Copper Mountain Project in Wyoming. The company recently announced the staking of the Knob claims in Wyoming, comprising 52...

22 minutes ago